Malignant hyperthermia: Considerations for the general surgeon

Canadian Journal of Surgery

Volumn 45, Issue 5, 2002, Pages 369-372

  Heggie, Jane E ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; DANTROLENE; FUROSEMIDE; MANNITOL; NARCOTIC AGENT; PROPOFOL;

ANESTHESIA COMPLICATION; CLINICAL FEATURE; CLINICAL PRACTICE; DISEASE PREDISPOSITION; HUMAN; MALIGNANT HYPERTHERMIA; PEROPERATIVE CARE; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PREOPERATIVE CARE; REVIEW;

ANESTHETICS, INHALATION; BIOPSY; DANTROLENE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALIGNANT HYPERTHERMIA; MONITORING, PHYSIOLOGIC; MUSCLE RELAXANTS, CENTRAL; MUSCLE, SKELETAL; NEUROMUSCULAR NONDEPOLARIZING AGENTS; SURGERY;

EID: 0036815319     PISSN: 0008428X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (5)

1. Larach MG. Should we reassess the susceptibility of MH patients? Can J Anaesth 1997;44:685-8.
2. Larach MG, Localio AR, Allen GC, Denborough MA, Ellis FR, Gronert GA, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994;80:771-9.
3. Lazzell VA, Carr AS, Lerman J, Burrows FA, Creighton RE. The incidence of masseter muscle rigidity after succimylcholine in infants and children. Can J Anaesth 1994;41:475-9.
4. MacLennan DH, Duff C, Zorzato F. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 1990;343:559-61.
5. MacLennan DH, Phillips MS. Malignant hyperthermia. Science 1992;256:789-94.